Last Updated: September 24, 2026

Details for Patent: 9,603,951


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,603,951 protect, and when does it expire?

Patent 9,603,951 protects FLYRCADO and is included in one NDA.

This patent has fifty patent family members in nineteen countries.

Summary for Patent: 9,603,951
Title:Methods and apparatus for synthesizing imaging agents, and intermediates thereof
Abstract:The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.
Inventor(s):Joel Lazewatsky, Marybeth Devine
Assignee: Lantheus Medical Imaging Inc
Application Number:US14/561,594
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 9,603,951

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ge Hlthcare FLYRCADO flurpiridaz f-18 SOLUTION;INTRAVENOUS 215168-001 Sep 27, 2024 RX Yes Yes 9,603,951 ⤷  Start Trial METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) FOR CARDIAC IMAGING ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.